• Cadence Pharmaceuticals Inc., of San Diego, said the U.S. Patent and Trademark Office (USPTO) has issued a non-final, initial office action in the ex parte reexamination of U.S. Patent No. 6,028,222, or the '222 patent, one of the two licensed patents covering Ofirmev (acetaminophen) injection.